Investors & media
Financial data
Find the latest press releases, financial information, and performance updates.
Transforming rare disease care
We are a global specialty biopharmaceutical company expanding possibilities for people with rare diseases. With 50 years of experience in applying our scientific expertise and unique technologies to research, we continue to develop next-generation treatments and expand our global footprint to transform the lives of patients worldwide.
Newsroom
2025.10.30
FY2025 Second quarter results briefing session material
2025.10.30
FY2025-Q2 Financial report (Jul. 1-Sep. 30, 2025)
2025.10.17
Shin Ashida of JCR Pharmaceuticals named Kansai Regional Representative in EY Entrepreneur of The Year(TM) 2025 Japan
2025.10.07
JCR Pharmaceuticals enhances delivery of AAV gene therapy to central nervous system and muscle with novel capsid engineering platform technology
2025.10.01
JCR Pharmaceuticals announces licensing agreement with Menagen to commercialize Agalsidase Beta BS I.V. Infusion [JCR] across nine MENAT markets
Performance data
JCR Pharmaceuticals (4552.T)
Tokyo Currency in JPY
598.00
-57.00
(-8.70%)
Last updated 10/31/2025 at TSE market close
Quarterly results
Driven by science and compassion, we tackle some of the most complex challenges in rare disease. Every solution we develop is grounded in insight into the genetic and biological foundations of the conditions we aim to treat.
Contact us
Investors & media